AzTrials
AzTrials

Androgenetic AlopeciaPhase 3NCT01231607

Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia

A Phase 3 study testing 1mg Finasteride active, 0.02mg dutasteride and 0.1mg dutasteride in people with Androgenetic Alopecia, run by GlaxoSmithKline at 39 sites in 9 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this six month study is to show that dutasteride is safe and more effective than placebo, and at least as safe and effective as finasteride in treating hair loss in men with androgenetic alopecia. Three doses of dutasteride will be investigated. Read more about this study

Who is it for?
Ages 20 to 50 years, men only
Conditions the study is for
Androgenetic Alopecia
What is being tested?
1mg Finasteride active, 0.02mg dutasteride and 0.1mg dutasteride
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
917 participants
Where
39 sitesin 9 countries
Study dates
28 Oct 2010to 28 Feb 2012
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 50 years
  • Men only
  • No healthy volunteers
  • Adult

Who may be able to join

  • Norwood-Hamilton Type III vertex, IV, or V

Who cannot join

  • History or evidence of hair loss other than androgenetic alopecia
  • Scarring of the scalp
  • Use of dutasteride in previous 18 months
  • Use of finasteride within previous 12 months
  • Hair transplantation or hair weaving within 6 months
  • Use of Minoxidil within previous 6 months
Show all 10Show fewer
  • Use of drugs with anti-androgenetic/androgenetic properties within previous 6 months
  • Use of Drugs that cause hypertrichosis or hypotrichosis within previous 6 months
  • Light or laser treatment of scalp within previous 3 months
  • Cosmetic products aimed at improving or correcting signs of hair loss within previous 2 weeks

Trial locations and contacts

39 sites in 9 countries.

39 sites in 9 countries

Mexico6 sites
  • GSK Investigational Site

    Mazatlan, Sinaloa, Sinaloa, 82126

  • GSK Investigational Site

    Mexico City, 03720

  • GSK Investigational Site

    Mexico City, 06780

  • GSK Investigational Site

    Monterrey, Nuevo León, 64460

  • GSK Investigational Site

    Naucalpan, State of Mexico, 11200

  • GSK Investigational Site

    Zapopan, Jalisco, Jalisco, 45190

Other trials in Mexico

Argentina5 sites
  • GSK Investigational Site

    Buenos Aires, 1425

  • GSK Investigational Site

    Buenos Aires, C1114AAP

  • GSK Investigational Site

    CABA, Buenos Aires, C1055AAO

  • GSK Investigational Site

    Ciudad Autonoma de Buenos Aires, Buenos Aires, C1425BEA

  • GSK Investigational Site

    La Boca, Buenos Aires, C1155AHD

Other trials in Argentina

Japan5 sites
  • GSK Investigational Site

    Fukuoka, 812-0025

  • GSK Investigational Site

    Osaka, 530-0057

  • GSK Investigational Site

    Osaka, 532-0003

  • GSK Investigational Site

    Tokyo, 103-0028

  • GSK Investigational Site

    Tokyo, 160-0022

Other trials in Japan

Philippines5 sites
  • GSK Investigational Site

    Makati City, 1200

  • GSK Investigational Site

    Manila, 1000

  • GSK Investigational Site

    Quezon City, 1113

  • GSK Investigational Site

    Quezon City

  • GSK Investigational Site

    Tanauan City, Batangas, 4232

Other trials in Philippines

Russia5 sites
  • GSK Investigational Site

    Moscow, 107076

  • GSK Investigational Site

    Nizhny Novgorod, 603950

  • GSK Investigational Site

    Ryazan, 390046

  • GSK Investigational Site

    Saint Petersburg, 196084

  • GSK Investigational Site

    St'Petersburg, 192102

Other trials in Russia

Taiwan4 sites
  • GSK Investigational Site

    Tainan, 70403

  • GSK Investigational Site

    Taipei, 105

  • GSK Investigational Site

    Taipei, 220

  • GSK Investigational Site

    Taipei

Other trials in Taiwan

Thailand4 sites
  • GSK Investigational Site

    Bangkoknoi Bangkok, 10700

  • GSK Investigational Site

    Chiang Mai, 50200

  • GSK Investigational Site

    Patumwan Bangkok, 10330

  • GSK Investigational Site

    Rajthevee Bangkok, 10400

Other trials in Thailand

Peru3 sites
  • GSK Investigational Site

    Lima, Lima Province, Lima 41

  • GSK Investigational Site

    Lima, Lima 27

  • GSK Investigational Site

    Lima Cercado, LIMA 01

Other trials in Peru

Chile2 sites
  • GSK Investigational Site

    Santiago, Región Metro de Santiago, 7580206

  • GSK Investigational Site

    Viña del Mar, Valparaiso, 252 0000

Other trials in Chile

About this study

Official title: A Study of the Efficacy and Safety of Multiple Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects With Androgenetic Alopecia

The purpose of this six month study is to show that dutasteride is safe and more effective than placebo, and at least as safe and effective as finasteride in treating hair loss in men with androgenetic alopecia. Three doses of dutasteride will be investigated.

Read the detailed description

Androgenetic alopecia is a common, androgen-induced, pattern of progressive loss of scalp hair with an onset at any age after puberty in genetically predisposed people. The influence of androgens on scalp hair growth is mediated by local and systemic conversion of testosterone to dihydrotestosterone , by the enzyme 5 alpha-reductase. 5 alpha-reductase has been shown to exist as 2 isoenzyme forms, Type 1 and Type 2. Type 1 is predominantly located in the skin, both in the hair follicles and sebaceous glands, and is also found in the liver and kidney . Type 2 is the dominant form in male genitalia, including the prostate, although it has also been reported to be present in the inner root sheath of the hair follicle. The presence of both isoenzymes in the hair follicles suggests that both forms are likely to be important in the pathogenesis and treatment of androgenetic alopecia. Inhibition of both Type 1 and Type 2 5 alpha-reductase may be expected to more effectively reduce systemic and local dihydrotestosterone levels than inhibition of either isoenzyme alone.

Finasteride is a selective Type 2 5 alpha-reductase inhibitor that is currently the only approved oral treatment for androgenetic alopecia worldwide. Dutasteride inhibits both Type 1 and Type 2 5alpha-reductase and is approved in more than 80 countries for the treatment of benign prostatic hyperplasia, and in Korea for the treatment of hair loss. Dutasteride is approximately 3 times as potent as finasteride at inhibiting Type 2 5 alpha-reductase and more than 100 times as potent at inhibiting Type 1 5 alpha-reductase.

In a Phase II double-blind, placebo-controlled clinical study (ARIA2004) conducted in the United States, dutasteride demonstrated significant increases in target area hair count, as compared with placebo, as early as 12 weeks. In a Phase III double- blind, placebo-controlled clinical study conducted in Korea, dutasteride 0.5 milligram (mg) demonstrated significant increases in target area hair count, as compared with placebo, at 24 weeks. This 6 month study is being conducted to provide additional evidence of the efficacy and safety of three doses of dutasteride (0.02, 0.1 and 0.5mg) in the treatment of androgenetic alopecia, and more specifically, to characterize the dose-response relationship in an ethnically-diverse population. Treatment arms will be equally balanced with approximately 180 per arm.

Being tested
1mg Finasteride active, 0.02mg dutasteride, 0.1mg dutasteride, 0.5mg dutasteride, Finasteride placebo
Medical subject headings
Alopecia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 1mg Finasteride activeDrug

    1mg finasteride active, by mouth once daily

  • 0.02mg dutasterideDrug

    0.02mg dutasteride active, by mouth once daily

  • 0.1mg dutasterideDrug

    0.1mg dutasteride active, by mouth once daily

  • 0.5mg dutasterideDrug

    0.5mg dutasteride active, by mouth once daily

  • Finasteride placeboDrug

    finasteride placebo, by mouth once daily

  • Dutasteride placeboDrug

    dutasteride placebo, by mouth once daily

Study groups in NCT01231607
Study groupRoleWhat they receive
1mg FinasterideActive comparator1mg finasteride active plus dutasteride placebo, by mouth once daily
Receives: Drug: 1mg Finasteride active; Drug: Dutasteride placebo
0.02mg DutasterideActive comparator0.02mg dutasteride active plus finasteride placebo, by mouth once daily
Receives: Drug: 0.02mg dutasteride; Drug: Finasteride placebo
0.1mg DutasterideActive comparator0.1mg dutasteride active plus finasteride placebo, by mouth once daily
Receives: Drug: 0.1mg dutasteride; Drug: Finasteride placebo
0.5mg DutasterideActive comparator0.5mg dutasteride active plus finasteride placebo, by mouth once daily
Receives: Drug: 0.5mg dutasteride; Drug: Finasteride placebo
PlaceboPlacebo comparator1mg finasteride placebo plus dutasteride placebo, by mouth once daily
Receives: Drug: Finasteride placebo; Drug: Dutasteride placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline (BL) in Target Area Hair Count (HC) Within a 2.54 Centimeter (cm) (1 Inch) Diameter Circle at the Vertex at Week 24, as Assessed by Macrophotographic Technique (MT)

    The primary target area HC was based on the nonvellus hair (>=30 micrometers [μm] in width; thick and noticeable hair) count within a target 2.54 cm (1 inch) diameter circle at the vertex (crown, topmost part of the head). A cosmetic ink dot was placed by tattoo at BL so that the same area could be identified at BL and post-BL. If the ink dot faded, it was re-done in exactly the same location to ensure visibility for subsequent photographs. For the MT, hair was clipped before each photograph; HC was based on hair follicles in the photographs. Change from BL=Week 24 value minus the BL value.

    Measured: Baseline and Week 24

Secondary outcomes (16)
  1. Change From Baseline in Target Area Hair Count Within a 1.13 cm (0.44 Inch) Diameter Circle at the Vertex at Week 24, as Assessed by MT

    The primary target area HC was based on the nonvellus hair (>=30 micrometers [μm] in width; thick and noticeable hair) count within a target 1.13 cm (0.44 inch) diameter circle at the vertex (crown, topmost part of the head). A cosmetic ink dot was placed by tattoo at BL so that the same area could be identified at BL and post-BL. If the ink dot faded, it was re-done in exactly the same location to ensure visibility for subsequent photographs. For the MT, hair was clipped before each photograph; HC was based on hair follicles in the photographs. Change from BL=Week 24 value minus the BL value.

    Measured: Baseline and Week 24

  2. Change From Baseline in Target Area Hair Count Within a 2.54 cm (1 Inch) Diameter Circle at the Vertex at Week 12 as Assessed by MT

    The primary target area HC was based on the nonvellus hair (>=30 micrometers [μm] in width; thick and noticeable hair) count within a target 2.54 cm (1 inch) diameter circle at the vertex (crown, topmost part of the head). A cosmetic ink dot was placed by tattoo at BL so that the same area could be identified at BL and post-BL. If the ink dot faded, it was re-done in exactly the same location to ensure visibility for subsequent photographs. For the MT, hair was clipped before each photograph; HC was based on hair follicles in the photographs. Change from BL=Week 12 value minus the BL value.

    Measured: Baseline and Week 12

  3. Change From Baseline in Target Area Hair Count Within a 1.13 cm (0.44 Inch) Diameter Circle at the Vertex, as Assessed by MT at Week 12

    The primary target area HC was based on the nonvellus hair (>=30 micrometers [μm] in width; thick and noticeable hair) count within a target 1.13 cm (0.44 inch) diameter circle at the vertex (crown, topmost part of the head). A cosmetic ink dot was placed by tattoo at BL so that the same area could be identified at BL and post-BL. If the ink dot faded, it was re-done in exactly the same location to ensure visibility for subsequent photographs. For the MT, hair was clipped before each photograph; HC was based on hair follicles in the photographs. Change from BL=Week 12 value minus the BL value.

    Measured: Baseline and Week 12

  4. Change From Baseline in Target Area Hair Width Within a 2.54 cm (1 Inch) Diameter Circle at the Vertex at Week 12 and Week 24, as Assessed by MT

    The target area hair width was the sum of all nonvellus hairs (>=30 µm in width; thick and noticeable hair) within a target 2.54 cm (1 inch) diameter circle at the vertex (crown, topmost part of the head). For the MT, hair was clipped before each photograph. A cosmetic ink dot was placed by tattoo at Baseline so that the same area could be identified at Baseline and post-Baseline. If the ink dot faded, it was re-done in exactly the same location to ensure it was visible for subsequent photographs. Change from Baseline was calculated as the Week 12 or Week 24 value minus the Baseline value.

    Measured: Baseline, Week 12, and Week 24

  5. Change From Baseline in Target Area Hair Width Within a 1.13 cm (0.44 Inch) Diameter Circle at the Vertex at Week 12 and Week 24, as Assessed by MT

    The target area hair width was the sum of all nonvellus hairs (>=30 µm in width; thick and noticeable hair) within a target 1.13 cm (0.44 inch) diameter circle at the vertex (crown, topmost part of the head). For the MT, hair was clipped before each photograph. A cosmetic ink dot was placed by tattoo at Baseline so that the same area could be identified at Baseline and post-Baseline. If the ink dot faded, it was re-done in exactly the same location to ensure it was visible for subsequent photographs. Change from Baseline was calculated as the Week 12 or Week 24 value minus the Baseline value.

    Measured: Baseline, Week 12, and Week 24

  6. Change From Baseline in Terminal Hair Count (THC) Within a 2.54 cm (1 Inch) Diameter Circle at the Vertex at Week 12 and Week 24, as Assessed by MT

    The THC (thick, long, and dark hair) was the sum of all nonvellus hairs (>=60 μm in width; thick and noticeable hair) within a target 2.54 cm (1 inch) diameter circle at the vertex (crown, topmost part of the head). A cosmetic ink dot was placed by tattoo at BL so that the same area could be identified at BL and post-BL. If the ink dot faded, it was re-done in exactly the same location to ensure visibility for subsequent photographs. For the MT, hair was clipped before each photograph; HC was based on the hair follicles in the photographs. Change from BL=Week 12/Week 24 value minus BL value.

    Measured: Baseline, Week 12, and Week 24

  7. Change From Baseline in Terminal Hair Count Within a 1.13 cm (0.44 Inch) Diameter Circle at the Vertex at Week 12 and Week 24, as Assessed by MT

    The THC (thick, long, and dark hair) was the sum of all nonvellus hairs (>=60 μm in width; thick and noticeable hair) within a target 1.13 cm (0.44 inch) diameter circle at the vertex (crown, topmost part of the head). A cosmetic ink dot was placed by tattoo at BL so that the same area could be identified at BL and post-BL. If the ink dot faded, it was re-done in exactly the same location to ensure visibility for subsequent photographs. For the MT, hair was clipped before each photograph; HC was based on hair follicles in the photographs. Change from BL=Week 12/Week 24 value minus BL value.

    Measured: Baseline, Week 12, and Week 24

  8. Global Assessment of Improvement From Baseline to Week 24 Assessed for Vertex and Frontal Views Separately

    A central panel of 3 dermatologists independently assessed change in hair growth from Baseline to Week 24 using a 7-point scale: greatly decreased (-3), moderately decreased (-2), slightly decreased (-1), no change (0), slightly increased (1), moderately increased (2), and greatly increased (3). The median score, across the 3 panel members, is summarized. This assessment was performed by comparing the global photographs obtained at Baseline with those subsequently obtained at Week 24. This assessment was made separately based on the global photography of the vertex and frontal views.

    Measured: Baseline and Week 24

  9. Change From Baseline in Investigator Photographic Assessment Questionnaire (IPAQ) Scores Assessed at Week 12 for Vertex and Frontal Views Separately

    The IPAQ was completed by the Investigator or designee by comparing the global photographs obtained at Baseline with those obtained at Week 12. This assessment was made separately based on the global photography of the vertex and frontal views. The change from Baseline in hair growth was assessed using the following 7-point scale: -3 = greatly decreased, -2 = moderately decreased, -1 = slightly decreased, 0 = no change, +1 = slightly increased, +2 = moderately increased, +3 = greatly increased.

    Measured: Baseline and Week 12

  10. Change From Baseline in Investigator Photographic Assessment Questionnaire (IPAQ) Scores Assessed at Week 24 for Vertex and Frontal Views Separately

    The IPAQ was completed by the Investigator or designee by comparing the global photographs obtained at Baseline with those obtained at Week 12. This assessment was made separately based on the global photography of the vertex and frontal views. The change from Baseline in hair growth was assessed using the following 7-point scale: -3 = greatly decreased, -2 = moderately decreased, -1 = slightly decreased, 0 = no change, +1 = slightly increased, +2 = moderately increased, +3 = greatly increased.

    Measured: Baseline and Week 24

  11. Number of Participants With the Indicated Change From Baseline (BL) in the Stage (S) of Androgenic Alopecia (AGA) According to the Norwood-Hamilton Scale at Week 12 (W12)

    The investigator/designee assessed the stage (Stage I to Stage VII) of AGA (i.e., male pattern baldness [MPB]) by utilizing the Norwood-Hamilton scale, used to measure the progression of MPB. Stage VII indicates worse balding than stage I. Assessment was made by direct visual examination (aided by pictures) of the participant at Baseline and Week 12 (W12). "v," vertex; most of the hair loss (commonly seen with advancing age) is on the vertex. "a," type a variant; major features are (1) the entire anterior hairline border recedes in unison; (2) there is no simultaneous balding of the vertex.

    Measured: Baseline and Week 12

  12. Number of Participants With the Indicated Change From Baseline (BL) in the Stage (S) of Androgenic Alopecia (AGA) According to the Norwood-Hamilton Scale at Week 24

    The investigator/designee assessed the stage (Stage I to Stage VII) of AGA (i.e., male pattern baldness [MPB]) by utilizing the Norwood-Hamilton scale, used to measure the progression of MPB. Stage VII indicates worse balding than stage I. Assessment was made by direct visual examination (aided by pictures) of the participant at Baseline and Week 24 (W24). "v," vertex; most of the hair loss (commonly seen with advancing age) is on the vertex. "a," type a variant; major features are (1) the entire anterior hairline border recedes in unison; (2) there is no simultaneous balding of the vertex.

    Measured: Baseline and Week 24

  13. Serum Concentration of Dutasteride at Week 12, Week 24, and Follow-up (Week 26)

    Serum concentrations of dutasteride were measured after 12 weeks and 24 weeks of study treatment and at follow-up (approximately 2 weeks after the last dose of study treatment).

    Measured: Week 12, Week 24, and Week 26

  14. Serum Dihydrotestosterone (DHT) at Week 12, Week 24, and Follow-up (Week 26)

    Serum concentrations of DHT were measured after 12 weeks and 24 weeks of study treatment and at follow-up (approximately 2 weeks after the last dose of study treatment).

    Measured: Week 12, Week 24, and Week 26

  15. Change From Baseline in Hair Growth Index (HGI) Scores at Weeks 12 and 24

    Participant-perceived change in HG was assessed by 3 questions (each scored on a 7-point scale) on a health outcome questionnaire: "Since the start of treatment, when I look at my thinning area, I can see...", "Since the start of treatment, my hair now covers…", and "Since the start of treatment, the appearance (thickness/quality/amount) of the thinning area on my head is…" -3, Much less; -2, Moderately less; -1, Slightly less; 0, The same amount; 1, Slightly more; 2, Moderately more; 3, Much more scalp. The scores for the 3 questions were summed to obtain the HGI total score (-9 to 9).

    Measured: Baseline, Week 12, and Week 24

  16. Change From Baseline in Total Hair Growth Satisfaction Scale (HGSS) Scores at Weeks 12 and 24

    Participant satisfaction with hair appearance/growth was assessed by 5 questions (each scored on a 7-point scale: How satisfied do you feel about: [1] The overall appearance of your hair; [2] The appearance of the thinning area[s] [TAs] on your head; [3] The amount of scalp that can be seen in the TAs; [4] The amount of hair in the TAs; [5] The growth of hair in the TAs): -3, Very dissatisfied (DS); -2, DS; -1, Somewhat DS; 0, Neutral (neither satisfied nor DS); 1, Somewhat satisfied (SA); 2, SA; 3, Very SA. The scores for the 5 questions were summed to obtain the HGSS total score (-15 to 15).

    Measured: Baseline, Week 12, and Week 24

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Nov 2010 (estimated)
  2. Study start28 Oct 2010
  3. Primary completion1 Feb 2012
  4. Study completion28 Feb 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
917 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01231607
Sponsor's protocol ID
114263
Status last verified
Jun 2018
First submitted
28 Oct 2010
Last updated
10 Aug 2018
Data monitoring committee
No
Individual data sharing
Yes: Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing 1mg Finasteride active, 0.02mg dutasteride and 0.1mg dutasteride in people with Androgenetic Alopecia, run by GlaxoSmithKline at 39 sites in 9 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Aug 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 39 sites in Mexico, Argentina, Japan, Philippines, Russia and 4 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 4 Oct 2012). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline (BL) in Target Area Hair Count (HC) Within a 2.54 Centimeter (cm) (1 Inch) Diameter Circle at the Vertex at Week 24, as Assessed by Macrophotographic Technique (MT) (time frame: Baseline and Week 24). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Aug 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in